Previous Article | Next Article 
Infection and Immunity, December 1999, p. 6487-6495, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Species Specificity of Plasminogen Activation and Acquisition of
Surface-Associated Proteolytic Activity by Group C Streptococci
Grown in Plasma
Brett
Schroeder,1
Michael D. P.
Boyle,2
Barbara
R.
Sheerin,3
Atwood C.
Asbury,3 and
Richard
Lottenberg1,*
Division of Hematology and Oncology,
Department of Medicine, University of Florida College of
Medicine,1 and College of Veterinary
Medicine, University of Florida,3 Gainesville,
Florida 32610, and Department of Microbiology and
Immunology, Medical College of Ohio, Toledo, Ohio
436142
Received 13 August 1999/Accepted 23 September 1999
 |
ABSTRACT |
Our laboratory previously demonstrated that group C streptococcal
isolates from humans and horses secrete streptokinases that preferentially activate plasminogens reflecting the origin of the
isolates. To analyze the significance of these findings, series of
streptokinase-producing Streptococcus equisimilis isolates recovered from humans and horses were examined. Southern blot analysis
revealed that chromosomal DNA of the streptococcal isolates from humans
reacted exclusively with a skchu probe and that
chromosomal DNA of streptococcal isolates from horses reacted
preferentially with an skceq probe in a
distinct pattern. The streptococcal isolates were examined for the
ability to acquire surface-bound plasmin-like activity when grown in
the presence of human or equine plasma. Each of eight isolates from
humans acquired significant enzymatic activity only when grown in the
presence of human plasma, while each of eight isolates from horses
acquired activity only when grown in the presence of equine plasma.
Analysis of bacterial and host protein requirements indicated critical
roles for streptokinase, activatable plasminogen, and fibrinogen. These
requirements may explain why certain streptococcal isolates cause
disease only in a limited number of mammalian hosts.
 |
INTRODUCTION |
It is well established that the
plasmin(ogen) system is responsible for the degradation of fibrin, a
major constituent of blood clots (10). Recently, evidence
indicating that it also plays an important role in a variety of
biological processes characterized by tissue remodeling and migration
of cells has accumulated (25, 27-31). Plasminogen is a
glycoprotein found in circulating blood and in extravascular spaces
(10, 35). The cleavage of plasminogen by specific
plasminogen activators generates plasmin, a serine protease with broad
substrate specificity. Plasmin can hydrolyze fibrin and extracellular
matrix proteins as well as activate latent metalloproteinases. Under
normal physiological conditions the generation of plasmin and the
expression of its enzymatic activity are tightly controlled (10,
35). Specific host inhibitors of plasminogen activators and
plasmin are particularly important in limiting plasmin activity
(8, 14, 28). For a variety of mammalian cells, it has been
demonstrated that assembly of plasmin(ogen) system components on the
surface leads to the generation of cell-associated plasmin activity
even in the presence of physiological inhibitors (27, 30).
Our laboratory has demonstrated that clinical and laboratory strains of
group A streptococci, when grown in the presence of human plasma,
acquired cell surface-associated enzymatic activity dependent on both
the cellular production of streptokinase, a secreted plasminogen
activator, and the presence of plasminogen in the culture medium
(9, 18, 37). A role for human fibrinogen as a cofactor has
also been documented (9, 38). The plasmin-like activity was
captured by the bacteria prior to consumption of
2-antiplasmin, the primary physiological inhibitor of
plasmin (18, 37). By comparing an isogenic mutant lacking
streptokinase production to wild-type group A or group C streptococci,
a number of investigators demonstrated that there was an absolute
requirement for streptokinase to generate this type of
surface-associated enzymatic activity (9, 20).
Streptococcus pyogenes group A bacteria are pathogens with a
host range essentially limited to humans, whereas group C streptococci infect a variety of mammals including humans. Previously we
demonstrated that group C streptococcal isolates produce streptokinases
that preferentially activate plasminogens reflecting the origin of the
isolate (24). For example, group C isolates recovered from horses efficiently activate equine plasminogen but do not activate human or porcine plasminogens efficiently (24). Furthermore, we purified streptokinase produced by Streptococcus
equisimilis organisms isolated from a horse and demonstrated that
the molecule was structurally distinct from streptokinase produced by
streptococci isolated from humans (26). One would predict
that if the streptokinase-dependent generation of cell
surface-associated proteolytic activity is important in the infectious
process, group C streptococci from various hosts would be capable of
acquiring this enzymatic activity also in a species-specific manner. In
this study, we examined the ability of group C streptococci isolated
from humans and horses to capture plasmin-like activity when grown in
plasma and addressed the species specificity of streptokinase in the
interaction of bacteria with plasminogen and other host plasma proteins.
 |
MATERIALS AND METHODS |
Reagents.
Todd-Hewitt broth (THB) was obtained from Difco
Laboratories (Detroit, Mich.) and prepared according to the formulation
of the manufacturer. Chemically defined medium for streptococci was obtained from Hazelton Research Products (Lenexa, Kans.) and was prepared according to the formulation of van de Rijn and Kessler (34). Ultrafiltration of THB was performed by utilizing a
PM-10 Diaflo membrane (Amicon Corp., Danvers, Mass.), and the filtrate (Mr < 10,000) was added to the chemically
defined medium at 10% of the total volume. Human fresh-frozen plasma
was obtained from Civitan Regional Blood Center, Gainesville, Fla., and
aliquots were stored at
20°C. Equine plasma was collected from
normal, healthy horses by venipuncture. Blood was placed immediately
into 1/10 volume of 3.8% sodium citrate and centrifuged to prepare plasma, and aliquots were stored at
20°C. Plasminogen-depleted plasma was prepared by passage over a lysine-Sepharose column. The
plasmin-selective chromogenic substrate
H-D-valyl-L-leucyl-lysine-paranitroaniline dihydrochloride (S-2251) was obtained from Pharmacia/Hoefer (Franklin, Ohio). All other reagents were from Sigma Chemical Company (St. Louis,
Mo.).
Bacterial isolates.
The study comprised 16 group C S. equisimilis isolates of human or equine origin (Table
1). Sugar fermentation reactions with
trehalose, sorbitol, and lactose confirmed the species identification (12). Among the eight S. equisimilis isolates of
human origin, six were obtained from Shands Hospital, Gainesville,
Fla.; 26RP66 was obtained from Rockefeller University, New York, N.Y.;
and 12449 was obtained from the American Type Culture Collection, Manassas, Va. Seven of the eight S. equisimilis isolates of
equine origin were kindly provided by John Timoney, Gluck Equine
Research Center, Lexington, Ky., and VM-45 was from the University of
Florida College of Veterinary Medicine, Gainesville, Fla.
Plasminogens and fibrinogens.
Human Glu-plasminogen was
purchased from American Diagnostica, Greenwich, Conn. Human and equine
fibrinogen was purchased from Sigma and further purified by
lysine-Sepharose chromatography to remove any contaminating
plasminogen. Equine plasminogen was purified from plasma by
lysine-Sepharose chromatography, followed by molecular sieving
chromatography on a Sephadex G-100 column as previously described
(19). The concentrations of the purified proteins were
determined by measuring the absorbance at 280 nm by using an
absorptivity of 1.7 ml mg
1 cm
1.
Streptokinases.
A highly purified group C streptokinase that
efficiently activates human plasminogen but not equine plasminogen
(SKhu), Kabikinase, was a gift from KabiVitrum, A.B.,
Stockholm, Sweden. There was no carrier protein in this preparation,
and the streptokinase was found to be homogeneous by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis analysis
(16). Group C streptokinase that efficiently activates
equine plasminogen but not human plasminogen (SKeq) was
prepared from a group C streptococcal isolate of equine origin as
described by Nowicki et al. (26). Briefly, S. equisimilis isolate 87-542-W was grown as a standing culture in
200 ml of chemically defined medium. The pH of the culture was
monitored and maintained above 7.0. The supernatant was concentrated by passing it through a PM 10 filter (Amicon), discarding the eluate, and
applying the concentrate (Mr > 10,000) to
a column of immobilized human plasminogen as described previously
(26). After the column was washed, bound streptokinase was
eluted with 8 M urea. The streptokinase was extensively dialyzed into
20 mM HEPES and then stored as aliquots at
20°C. The concentration
of the SKeq was determined with BCA protein assay reagent
(Pierce, Rockford, Ill.), with bovine serum albumin as the standard.
The plasminogen activator activity of SK preparations was determined by
a standard assay (19).
Iodination of fibrinogen and measurement of bacterial fibrinogen
binding.
Fifty micrograms of human or equine fibrinogen was
radiolabeled with 125I as previously described
(32). The binding of radiolabeled fibrinogen to group C
streptococci was performed as follows. Individual cultures of eight
group C S. equisimilis isolates recovered from either humans
or horses were grown in 100 ml of THB overnight at 37°C as stationary
cultures. Cells were then pelleted by centrifugation at 10,000 × g for 20 min and washed twice in 100 ml of 10 mM
Veronal-buffered saline containing 0.1% gelatin, pH 7.35 (VBS-gel).
Bacteria were resuspended at 6% wet weight/volume in VBS-gel.
Approximately 50,000 cpm of radiolabeled human or equine fibrinogen was
added to the bacteria in a final volume of 200 µl to yield a final
bacterial concentration of 3% wet weight/volume. The bacteria were
incubated for 2 h at 37°C and then washed three times with 2 ml
of VBS-gel. Bound fibrinogen was quantified in a Beckman 4000 gamma counter.
Streptococcal genomic DNA isolation.
Streptococci were grown
from starter cultures, inoculated into 100 ml of THB (Difco
Laboratories) supplemented with 0.3% yeast extract (Difco) and 120 mM
glycine (Fisher Scientific), and grown overnight at 37°C as
stationary cultures. Cells were harvested by centrifugation and washed
once with 20 mM Tris-HCl, pH 8.2. After centrifugation, the pellet was
resuspended in a mixture of 3.2 ml of 20 mM Tris-HCl, pH 8.2, and 7 ml
of 24% polyethylene glycol 20000 (Fisher Scientific) in distilled
H2O. After the mixture was mixed, 3.5 ml of lysozyme (from
a 20-mg/ml solution in distilled H2O; Sigma Chemical Co.)
was added and the mixture was incubated at 37°C for 1 h with
occasional shaking. The solution was centrifuged at 17,500 × g for 10 min, and the pellet was resuspended in 10 mM
Tris-HCl-1 mM EDTA, pH 7.6. Next, 300 µl of 20% SDS was added, and
the mixture was incubated at 65°C for 15 min. Two hundred microliters
of RNase (10 mg/ml in distilled H2O) was added, and the
solution was mixed and then incubated at 37°C for 15 min. Next, 200 µl of proteinase K (10 mg/ml in distilled H2O;
Calbiochem, La Jolla, Calif.) was added, and the solution was mixed and
incubated at 37°C for 30 min. Cells were harvested by centrifugation
at 17,500 × g for 10 min, and the pellet was
discarded. The DNA was purified from the supernatant by
ultracentrifugation in cesium chloride (Gibco BRL, Gaithersburg, Md.).
DNA hybridization studies.
DNA probes for hybridization by
the technique of Southern (22) were generated by the
following methods. Plasmid pNC1, containing a 1,056-bp
EcoRI/PstI DNA insert with an internal coding
sequence of the streptokinase gene cloned from S. equisimilis H46A representing approximately 85% of the open
reading frame (ORF; designated skchu) (13,
21) was digested with EcoRI and PstI, and
the resulting DNA fragments were subjected to agarose gel
electrophoresis. The 1-kb EcoRI/PstI fragment was
excised, labeled, and used as a probe. Plasmid pBSTK22 contains a
2.9-kb BamHI/SauIIIA DNA insert harboring the
coding sequence of the streptokinase gene cloned from S. equisimilis 87-542-W (designated skceq).
The DNA fragment of interest was amplified by PCR. Primers 5'-GTAGGGCTATGTTTATTTTGCTAA-3' and
5'-GGTTTGCTTTTAGAAGCGCGTTATT-3' were used to amplify a
1,589-kb fragment containing the entire ORF of the gene comprising
skceq. The PCR product was purified with the
Wizard PCR Preps DNA purification system according to instructions of
the manufacturer (Promega Corporation, Madison, Wis.). Both fragments
were labeled with [
-32P]dCTP by using a random priming
kit according to the instructions of the manufacturer (Amersham,
Arlington Heights, Ill.).
Approximately 1 to 2 µg of genomic DNA from each of eight group C
streptococcal isolates from humans and eight group C isolates from
horses was digested to completion with HindIII, and DNA
fragments were separated in parallel 0.7% (wt/vol) agarose gels. The
DNA fragments were transferred to GeneScreen Plus nylon membranes by
the capillary blotting procedure according to the instructions of the
manufacturer (Du Pont, Boston, Mass.). One membrane was hybridized with
the skchu probe, while the other membrane was
hybridized with the skceq probe. Hybridization
was performed overnight at 45°C in 10% dextran sulfate-50%
formamide-0.5% SDS. Membranes were washed once at room
temperature with excess 2× SSC (150 mM NaCl-15 mM
Na3C6H5O7 · 2H2O) for 10 min. Two washes were then performed at the
hybridization temperature with 2× SSC containing 1% SDS for 20 min,
followed by two washes at room temperature with 0.2× SSC-1% SDS.
Membranes were exposed to X-ray film overnight at room temperature, and hybridizing bands were visualized by automated film developing.
Determination of bacterium-associated enzymatic activity.
Bacterial isolates were grown at 37°C overnight as stationary
cultures either in THB or a chemically defined medium containing 10%
THB ultrafiltrate (CDM). One hundred microliters of the stationary culture was added to a mixture containing 1.4 ml of medium and 0.6 ml
of human or equine plasma (final plasma concentration of 30%) or
VBS-gel. After incubation at 37°C for 6 h, the cells were harvested by centrifugation, washed three times in VBS-gel, and resuspended in 1 ml of the same buffer. The number of bacteria was
normalized by measuring the optical density at 550 nm and adjusting
with VBS-gel to an optical density of approximately 2.0. S-2251 was
added to yield a final concentration of 450 µM in a final volume of
400 µl. After incubation at 37°C, an equal volume of a 10% acetic
acid in VBS-gel solution was added to stop the reaction. The bacteria
were pelleted by centrifugation, and the absorbance of the
bacterium-free supernatant was determined spectrophotometrically at 405 nm.
The effects of exogenous streptokinase on bacterium-associated
enzymatic activity.
S. equisimilis isolates were grown in
THB or CDM to stationary phase at 37°C, as standing cultures.
Bacterial cultures were concentrated by centrifugation and washed in
sterile VBS-gel, and the numbers of bacteria were normalized by
measuring the optical density at 550 nm. In studies in which exogenous
SK was added to the culture medium, 100 µg of chloramphenicol/ml was
also added. Chloramphenicol allowed the effects of endogenous and
exogenous SK to be distinguished. The dose of chloramphenicol utilized
was found to be sufficient to prevent SK synthesis under these assay conditions. The bacteria were washed three times in VBS-gel and then
incubated with SKhu for 6 h at 37°C in CDM
containing 100 µg of chloramphenicol/ml and supplemented with either
30% human plasma, 30% equine plasma, or buffer alone. The final
concentration of the exogenous SKhu was 200 U/ml in a final
volume of 2 ml. The bacteria were washed twice in VBS-gel, and cell
surface-associated enzymatic activity was determined as previously described.
 |
RESULTS |
Characterization of the streptokinase genes in human and equine
group C isolates.
The initial studies were designed to compare the
skc genes in group C S. equisimilis isolates
recovered from humans and horses. Chromosomal DNA was isolated and
incubated with HindIII, and fragments were separated on
agarose gels as described in Materials and Methods. Separated fragments
were transferred to nylon membranes by the method of Southern and
probed with a streptokinase gene probe cloned from S. equisimilis H464A (skchu), isolated from a
human, representing approximately 85% of the ORF (21), or
the corresponding probe derived from 87-542-W
(skceq), an isolate from a horse. (For precise
details of these probes see Materials and Methods.) Chromosomal DNA
from all group C isolates recovered from human patients reacted with
the skchu gene probe and demonstrated reactivity
with a similar series of bands in all of the enzyme digests (Fig.
1). Similar blots of fragmented
chromosomal DNA from group C isolates recovered from equine sources
demonstrated no reactivity with the skchu gene
probe (Fig. 1).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 1.
DNA hybridization studies. Eight S. equisimilis isolates recovered from humans (A to H) and eight
S. equisimilis isolates recovered from horses (I to P) were
analyzed. For details of isolates see Table 1. (A) The membrane was
reacted with a probe consisting of the internal coding sequence (85%
of the ORF) of skchu. (B) The membrane was
reacted with a probe consisting of the gene comprising
skceq and its flanking sequence. For details of
the probe sequences, see Materials and Methods.
|
|
Studies utilizing the skceq probe derived from
isolate 87-542-W demonstrated reactivity with a similarly sized
fragment from each of the equine isolates; however, this probe showed
limited reactivity with the chromosomal DNA from any group C S. equisimilis organism isolated from humans. The pattern of reactive
bands in the HindIII digests of chromosomal DNA from
isolates recovered from humans or horses was distinct (Fig. 1). These
studies demonstrate that the gene encoding streptokinase in isolates
recovered from either humans or horses is well conserved but, in
agreement with earlier studies, that the genes encoding the plasminogen
activator in isolates recovered from humans differ markedly from those
in isolates recovered from horses (6). This fundamental
difference may explain the reason for the species-specific plasminogen
activation potential of these distinct gene products.
Analysis of the ability of human and equine group C streptococcal
isolates to acquire surface enzymatic activity when grown in homologous
plasma.
Previous studies had demonstrated that isolates recovered
from humans of group A and C streptococci could acquire a
plasminogen-dependent surface enzymatic activity when grown in human
plasma (18, 37). In preliminary studies we demonstrated that
human plasminogen was activated efficiently by SKhu, a
highly purified streptokinase from an isolate of human origin, whereas
equine plasminogen was activated efficiently only by SKeq,
a streptokinase purified from culture supernatant produced by S. equisimilis 87-542-W, an isolate from a horse (data not shown). Based on the difference in the streptokinase gene between isolates recovered from humans and horses shown in Fig. 1 and the reported difference in activation of the plasminogen activator between isolates
recovered from humans and horses (24), the next series of
studies were designed to compare the abilities of representative isolates to acquire enzymatic activity when grown in plasma obtained from the same species (homologous) from which the bacteria were originally recovered.
To determine if the ability to capture cell-associated enzymatic
activity, when grown in plasma from the same species as that of the
host from which the bacteria were isolated, was a common characteristic
of group C streptococci, eight isolates recovered from humans and eight
isolates recovered from horses were studied. The results presented in
Fig. 2A demonstrate that all of the
isolates recovered from humans, when grown in the presence of human
plasma, acquired significant enzymatic activity, as measured by the
ability of washed bacteria to cleave the synthetic substrate S-2251.
The same isolates grown in the presence of equine plasma were markedly less efficient in acquiring enzymatic activity. In a similar series of
studies using streptococcal isolates recovered from horses, only
isolates grown in the presence of equine plasma acquired measurable
enzymatic activity. When the same isolates were grown in human plasma,
acquisition of enzymatic activity was markedly reduced (Fig. 2B).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Surface-associated enzymatic activity acquired by
S. equisimilis isolates recovered from humans or horses
following incubation in either human or equine plasma. S. equisimilis isolates were grown in CDM containing buffer, 30%
human plasma, or 30% equine plasma. Cell-associated enzymatic activity
was determined as described in Materials and Methods. (A) Results for
S. equisimilis isolates recovered from humans. (B) Results
for S. equisimilis isolates recovered from horses. Error
bars are not depicted for standard deviations <0.1
A405 unit.
|
|
Bacterium-associated enzymatic activity was measured in all of these
assays by hydrolysis of the chromogenic substrate S-2251. This
substrate is sensitive to cleavage by plasmin or
streptokinase-plasmin(ogen) complexes; however, it can also be
hydrolyzed by other serine proteases that could potentially be produced
either by the bacteria or as a result of activation of a nonplasminogen
plasma component(s). Consequently, in the next series of experiments
the role of plasminogen in the acquisition of surface enzymatic
activity was determined. For these studies, representative group C
streptococcal isolates from human or equine sources were grown in the
presence of either homologous plasma or homologous plasma depleted of
plasminogen. Plasminogen-depleted plasma was prepared by passage of
plasma over a lysine-Sepharose column. A control sample of
plasminogen-depleted plasma reconstituted with purified plasminogen was
also included to ensure that the lysine-Sepharose treatment did not
deplete any critical component in addition to plasminogen.
The results of these studies for two representative isolates recovered
from humans (isolates A and B) and two representative isolates
recovered from horses (isolates I and J) are presented in Fig.
3 and 4,
respectively. In all cases, efficient acquisition of enzymatic activity
was observed only when bacteria were incubated with a homologous source
of plasma containing plasminogen.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Contribution of the presence of plasminogen in the
growth medium to the ability of S. equisimilis isolates from
humans to acquire surface-associated enzymatic activity. S. equisimilis isolates A and B were grown in CDM containing either
buffer, 30% human plasma, 30% human plasminogen-depleted plasma, or
30% human plasminogen-depleted plasma reconstituted with 2 µg of
human plasminogen/ml. Cell-associated enzymatic activity was determined
as described in Materials and Methods. Error bars are not depicted for
standard deviations <0.1 A405 unit.
|
|

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Contribution of the presence of plasminogen in the
growth medium to the ability of S. equisimilis isolates from
horses to acquire surface-associated enzymatic activity. S. equisimilis isolates I and J were grown in CDM containing either
buffer, 30% equine plasma, 30% equine plasminogen-depleted plasma, or
30% equine plasminogen-depleted plasma reconstituted with 2 µg of
equine plasminogen/ml. Cell-associated enzymatic activity was
determined as described in Materials and Methods. Error bars are not
depicted for standard deviations <0.1 A405
unit.
|
|
Contribution of streptokinase and species of plasminogen to
acquisition of enzymatic activity by group C streptococci.
The
results presented in Fig. 2 to 4 suggest that the ability of
streptokinase from different isolates to activate plasminogen could
account for the observed acquisition of cell-associated enzymatic
activity only when cells are grown in homologous plasma. Previous
studies have suggested that SK demonstrates a unique profile of species
specificity in its ability to activate different sources of mammalian
plasminogen (23, 24, 42). Consequently, the next series of
studies were designed to determine whether the ability of group C
streptococci to acquire enzymatic activity in heterologous plasma was
solely a function of SK or represented differences in plasmin-binding
potential between species. For these experiments a representative human
isolate (isolate A) and a representative equine isolate (isolate J)
were incubated in heterologous plasma, with or without the addition of
a source of Skhu. To distinguish the effect of endogenously
generated SK from that attributable to the addition of exogenous
SKhu, experiments were performed with both untreated
bacteria and bacteria pretreated with chloramphenicol to inhibit de
novo synthesis of the plasminogen activator. In preliminary studies a
concentration (100 µg/ml) of chloramphenicol significantly inhibited
acquisition of surface enzymatic activity for bacteria incubated with
homologous plasma (data not shown).
Untreated or chloramphenicol-treated bacteria were incubated in either
30% human or 30% equine plasma in the presence or absence of purified
SKhu (200 U), and the quantity of cell-associated enzymatic
activity, following a 1-h incubation at 37°C, was determined by the
ability of washed bacteria to cleave the synthetic substrate S-2251.
The results of these studies are presented in Fig.
5.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Effects of the addition of exogenous SKhu on
the ability of S. equisimilis isolates grown in human or
equine plasma to acquire surface-associated enzymatic activity. An
S. equisimilis isolate from a human (isolate A) and an
S. equisimilis isolate from a horse (isolate J) were
incubated in CDM containing 30% plasma alone, 30% plasma plus
chloramphenicol (Cam), or 30% plasma plus Cam and 200 U of
SKhu. (A) Results obtained for bacteria grown in the
presence of 30% human plasma; (B) results for bacteria grown in the
presence of 30% equine plasma. Cell-associated enzymatic activity was
determined as described in Materials and Methods. Error bars are not
depicted for standard deviations <0.1 A405
unit.
|
|
In agreement with the previous results, the human isolate grown in
human plasma acquired enzymatic activity. This activity was
significantly reduced by addition of chloramphenicol to the reaction
mixture (Fig. 5). Addition of exogenous SKhu to
chloramphenicol-treated bacteria incubated in the presence of human
plasma enhanced the acquisition of enzymatic activity. This result
indicates that production of SK is the limiting factor in the
acquisition of cell-surface enzymatic activity. In studies in which
equine plasma was substituted for human plasma, no enzymatic activity
was acquired by the human isolate in the presence or absence of
SKhu (Fig. 5).
When these studies were carried out with a representative group C
isolate recovered from a horse, a distinct pattern of acquisition of
enzymatic activity was observed. As expected, enzymatic activity could
be captured when the isolate was incubated in equine plasma. This
activity was inhibited by addition of chloramphenicol (Fig. 5). When
incubated in human plasma the isolate from a horse failed to acquire
any enzymatic activity; however, when incubated with human plasma and
SKhu, enzymatic activity could be captured (Fig. 5). These
studies indicate that an isolate recovered from a horse can bind either human or equine plasmin.
In a similar series of studies using SKeq in place of
SKhu, human group C isolates were found to be capable of
binding equine plasmin, and once again there was an absolute
requirement for a combination of SK and a species of activatable
plasminogen for any isolate to acquire surface enzymatic activity.
(data not shown).
These studies indicated that group C isolates could acquire enzymatic
activity only when incubated with a combination of plasma and
streptokinase which would enable plasminogen activation to occur. Based
on these results, group C isolates were capable of binding either human
or equine plasmin and their ability to acquire enzymatic activity is
predictable based on the species-specific activation preference of streptokinase.
Is streptokinase alone responsible for the species specificity of
acquisition of plasmin(ogen)-dependent cell-associated enzymatic
activity?
The studies presented to date indicate that in this
system, the species-specific acquisition of cell surface enzymatic
activity is dependent on both streptokinase and plasminogen. It is not clear, however, whether these two factors alone can account for all of
the species-specific properties of the system. Previous studies of the
ability of group A streptococci to acquire enzymatic activity when
grown in homologous plasma had identified a key role for fibrinogen
(9, 38). Consequently the ability of a representative group
C isolate of either human or equine origin to acquire enzymatic
activity when grown in homologous plasminogen-depleted serum
reconstituted with either human or equine plasminogen and/or human or
equine fibrinogen was studied. This experimental design permitted the
roles of both plasminogen and fibrinogen to be determined in a single assay.
The results of these preliminary experiments demonstrated that
acquisition of surface enzymatic activity for an isolate of human
origin (isolate A) required a source of both human plasminogen and
human fibrinogen. In similar experiments using a group C organism isolated from a horse (isolate J), efficient enzymatic activity was
observed only when the plasminogen-depleted equine serum was reconstituted with both equine plasminogen and fibrinogen (data not shown).
The next series of studies were conducted to assess the role of
fibrinogen in the species-selective acquisition of enzymatic activity
by group C isolates of human and equine origin. Preliminary results
indicated that growth of any bacterial isolate in homologous serum
demonstrated a marked reduction in acquisition of enzymatic activity
compared with growth in plasma (data not shown). In order to assess the
contribution of fibrinogen in these reactions, chloramphenicol-treated group C isolates recovered from either humans or horses were tested for
their ability to acquire enzymatic activity when grown in human or
equine fibrinogen in the presence of homologous plasminogen and a
source of SK that would result in plasminogen activation. The results
of these studies for one S. equisimilis isolate recovered from a human (Fig. 5A) and one S. equisimilis isolate
recovered from a horse (Fig. 5B) demonstrate that either human or
equine isolates were effective in capturing enzymatic activity when
grown with homologous fibrinogen and plasminogen and a source of SK that would activate the plasminogen. There was evidence for a species-specific contribution of fibrinogen for the isolate recovered from a human; however, this effect was not observed with an isolate recovered from a horse (Table 2). For the
isolate recovered from a horse, the presence of either human or equine
fibrinogen would facilitate the acquisition of enzymatic activity from
a reaction mixture which also contained SKeq and equine
plasminogen. For these studies excess SK was added to enable the
contribution of fibrinogen-SK-plasmin(ogen) binding to be
distinguished from direct binding of plasmin. In the presence of excess
SK no plasmin generated can bind directly to the bacteria (Table 2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Effect of different species of fibrinogen on the ability
of streptococcal group C isolates to acquire plasminogen-dependent
enzymatic activity
|
|
Parallel studies of the binding of radiolabeled human and equine
fibrinogen revealed that all of the group C S. equisimilis isolates recovered from humans demonstrated significant binding of
human fibrinogen but that binding of equine fibrinogen was comparatively less for all isolates (Fig.
6). By contrast, the fibrinogen-binding
potential of the equine isolates was variable and demonstrated no
definitive species preference. Some isolates (isolates L, M, and O)
recovered from horses bound human plasminogen more efficiently than
equine plasminogen. These results suggest that some of the observed
species specificity for the binding of plasmin(ogen)-dependent
enzymatic activity for the isolates of human origin (Table 2) may be
attributable to the fibrinogen-binding properties of each organism.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Binding of human and equine fibrinogen to group C
S. equisimilis isolates from humans and horses.
125I-labeled human or equine fibrinogen was added to each
group C isolate, and the quantity of fibrinogen bound was determined
following a 1-h incubation at 37°C. All estimates were carried out in
duplicate, and variations between samples were <5%.
|
|
 |
DISCUSSION |
The plasminogen activator streptokinase expressed by the majority
of groups A, C, and G streptococci demonstrates species specificity in
the range of mammalian plasminogen sources that can be activated
(23, 24, 42). Of particular interest has been the
observation that the plasminogen species activation profile predicts
the mammalian hosts that can be infected by a given organism (24). Streptococcal isolates recovered from humans secrete
SK which demonstrates efficient activation of human plasminogen but not
equine plasminogen, while isolates from horses produce a plasminogen activator that is efficient in activating equine plasminogen but lacks
the ability to efficiently activate human plasminogen (24). The epidemiological associations between SK activity and the species of
mammal subject to infection have suggested a possible cause-and-effect relationship. Plasmin(ogen) activation results in the generation of the
potent serine proteinase plasmin. This enzyme, although most frequently
associated with clot lysis, has a substrate range broader than that of
fibrin and is capable of degrading fibronectin, laminin, and other
components of the extracellular matrix, as well as being capable of
activating a number of proenzymes including collagenases and matrix
metalloproteinases (10, 29-31).
These properties of plasmin have been associated with a number of
normal and pathogenic processes in humans including tissue remodeling,
trophoblast implantation, wound healing, and the metastatic spread of
tumor cells (2, 29-31). Because of the diverse range of
potentially destructive activities of plasmin on normal tissue, the
generation and activity of this enzyme in the human host are subject to
extremely tight regulation by protease inhibitors. These include PAI 1 and PAI 2, which regulate the major eukaryotic plasminogen activator
proteins (14), as well as
2-antiplasmin, which regulates the enzymatic activity of any plasmin generated (8). As a consequence of these efficient regulatory systems, fluid phase plasmin activity is not normally observed under
physiological conditions. The action of plasmin on fibrin clots and
other substrates is only noted when plasmin is localized to a clot or
to a cell surface which facilitates escape from normal regulatory control.
Detailed biochemical analysis of the mechanism of activation of
plasminogen by SK has only been carried out for a streptokinase molecule purified from the culture medium of a group C isolate recovered from a human (7). This form of streptokinase is a unique plasminogen activator in that it is not enzymatic in its activator function. Rather, a 1:1 stoichiometric complex of SK and
plasminogen is formed (7). It is this complex that mediates the catalytic conversion of plasminogen to plasmin. This activation process cannot be regulated by host inhibitors. The only mechanism for
prevention of SK-dependent activation is to prevent the complex from
forming by the action of a specific anti-SK neutralizing antibody.
Despite this difference in the activation process, any fluid phase
plasmin generated by SK is quickly inactivated by
2-antiplasmin, although the activator complex itself
cannot be regulated (8). Only when all of the
2-antiplasmin is consumed will free plasmin be detected
in plasma. This so called "lytic state" has been achieved by
administration of high doses of SK to patients undergoing "clot
busting" therapy to treat myocardial infarctions and venous
thromboembolism (36). However, the concentration of SK
required to achieve a lytic state is 4 to 5 orders of magnitude greater
than the concentration of SK produced by 1010 streptococci.
Thus, it would be unrealistic to expect that this level of plasminogen
activation mediated by SK secretion could occur during a streptococcal infection.
Recent observations from our laboratory and others have demonstrated
that groups A, C, and G streptococci can bind human plasmin to a
high-affinity surface plasmin binding protein and that, once bound, the
enzyme cannot be regulated by
2-antiplasmin (15, 17, 18, 37, 38). These findings suggested that the activation of
plasminogen by SK might be part of a more complex pathway that facilitated acquisition of an unregulatable host enzymatic activity by
the bacteria. These properties could enhance bacterial colonization through the action of plasmin-unmasking adhesions on host cells or by
permitting invasion by degradation of basement membranes. Studies of
the interaction of group A streptococci with human plasma have
identified a number of different pathways by which these bacteria can
acquire surface enzymatic activity. These include (i) direct binding of
preformed plasmin (4, 5, 17, 33), (ii) a complex interaction
between a bacterial fibrinogen-binding protein and human fibrinogen,
which provides a cell surface anchor site for an SK-plasminogen complex
(9, 38), and (iii) a unique plasminogen-binding M protein
(PAM) expressed by a limited number of serotype isolates (1,
41). PAMs can bind plasminogen directly, and, once bound, the
protein can be activated by host plasminogen activators or SK. In all
cases, the resulting bacterium-associated plasmin activity cannot be
regulated by host
2-antiplasmin or other regulatory
serpins. For a detailed review of all of these pathways see reference
3.
In this study we have examined the contribution of the species-specific
activation of plasminogen to the ability of group C S. equisimilis isolates recovered from human patients and horses to
acquire enzymatic activity when the isolates were grown in either human
or equine plasma, in serum, or with purified plasma proteins. The
initial studies compared the respective skc genes in each
isolate and confirmed that there was a marked difference between the
skc genes of isolates from different sources. The genes
encoding SKhu, a plasminogen activator that efficiently
activates human plasminogen to plasmin, were closely related in all of
the isolates recovered from humans. However,
skchu was markedly different from the
skc present in the isolates recovered from horses. The
skceq sequence encodes a plasminogen activator
that activates equine plasminogen efficiently but fails to activate
human plasminogen efficiently. Among S. equisimilis isolates
recovered from either humans or horses, the skc genes were
closely related.
When each group C isolate was grown in homologous plasma (i.e.,
isolates recovered from humans and grown in the presence of human
plasma or isolates recovered from horses and grown in the presence of
an equine plasma), the ability to acquire surface enzymatic activity
was observed for all SK-secreting isolates. In all cases this activity
was dependent on the presence of an activatable source of plasminogen.
No isolate could acquire enzymatic activity when incubated in any
source of plasminogen-depleted plasma. Isolates from humans grown in
equine plasma failed to acquire significant enzymatic activity, while
all of the isolates from horses acquired surface enzymatic activity and
vice versa. The ability to acquire enzymatic activity was also shown to
be dependent on the production of a plasminogen activator by the bacteria. Inhibition of protein synthesis prevented any isolate grown
in homologous plasma from acquiring significant surface-associated enzymatic activity, and this property could be restored by addition of
the appropriate source of purified SK.
Studies of the ability of bacteria to acquire enzymatic activity when
incubated in homologous serum rather than plasma suggested a potential
role for plasma proteins in addition to plasminogen. Based on our
previous studies of group A streptococci (9, 37, 38)
fibrinogen was considered to be a potentially important cofactor. Other
studies of group A streptococcal virulence have also suggested that
fibrinogen binding is important (11, 39, 40). In the studies
evaluating a role for fibrinogen, a series of experiments were
performed with a purified protein system. Different combinations of
human or equine fibrinogen and/or plasminogen and SKhu or
SKeq indicated that an isolate recovered from a human
required a source of human fibrinogen to efficiently acquire enzymatic
activity. By contrast, isolates from horses could acquire enzymatic
activity in the presence of either human or equine fibrinogen and an
appropriate combination of homologous plasminogen and SK that would
result in plasminogen activation. The binding of fibrinogen was
variable among isolates. All of the isolates recovered from the humans studied demonstrated preferential reactivity with human fibrinogen, while for isolates recovered from horses there was no clear evidence for a species-specific fibrinogen-binding preference.
Taken together all the data presented in the study indicate that the
species specificity of SK results in a predictable pattern of
acquisition of cell-associated enzymatic activity for isolates grown in
different plasma sources. These studies are consistent with secreted SK
being part of a coupled system that is plasminogen and fibrinogen
dependent and that results in the ability of bacteria to acquire
surface enzymatic activity despite the presence of efficient host
regulators, such as
2-antiplasmin. These pathways are
highly efficient in allowing the organism to acquire surface enzymatic
activity following secretion of low levels of the plasminogen activator
SK compared with the levels of SK required to generate fluid phase
plasmin. From a comparison of the abilities of isolates from different
mammalian hosts to participate in these pathways, the species
specificity of SK-mediated plasminogen activation is apparent in all of
the experimental systems studied, and this finding provides further
support for the concept that bacterial plasminogen activators may be
key virulence factors in determining the host range for pathogenic
streptococcal infections.
 |
ACKNOWLEDGMENTS |
We thank John Timoney, Gluck Equine Research Center, for
providing group C S. equimilis isolates from horses; Joseph
Feretti, University of Oklahoma, Oklahoma City, for providing the
skchu probe; and Kenneth Johnston, Louisiana
State University Medical Center, New Orleans, for providing the
skceq probe.
This work was supported by grants from the National Institutes of
Health (HL 41898 and AI 43474) and a grant-in-aid from the American
Heart Association, Florida Affiliate.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610-0277. Phone: (352) 392-3000. Fax: (352) 392-8530. E-mail: lottenr{at}medicine.ufl.edu.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Berge, A., and U. Sjöbring.
1993.
PAM, a novel plasminogen-binding protein from Streptococcus pyogenes.
J. Biol. Chem.
268:25417-25424[Abstract/Free Full Text].
|
| 2.
|
Blasi, F., and P. Verde.
1990.
Urokinase-dependent cell surface proteolysis and cancer.
Cancer Biol.
1:117-126.
|
| 3.
|
Boyle, M. D. P., and R. Lottenberg.
1997.
Plasminogen activation by invasive human pathogens.
Thromb. Haemost.
77:1-10[Medline].
|
| 4.
|
Broder, C. C.,
R. Lottenberg, and M. D. P. Boyle.
1989.
Mapping of the human plasmin domain recognized by the unique plasmin receptor of group A streptococci.
Infect. Immun.
57:2597-2605[Abstract/Free Full Text].
|
| 5.
|
Broeseker, T. A.,
M. D. P. Boyle, and R. Lottenberg.
1988.
Characterization of the interaction of human plasmin with its specific receptor on a group A streptococcus.
Microb. Pathog.
5:19-27[Medline].
|
| 6.
|
Caballero, A.,
K. H. Johnston, and R. Lottenberg.
1995.
Cloning, expression and sequence analysis of streptokinases from Streptococcus equisimilis which preferentially activate equine and porcine plasminogens, abstr. B-42, p. 172.
In
Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C.
|
| 7.
|
Castellino, F. J.,
J. M. Sodetz,
W. J. Brockway, and G. E. Sefring, Jr.
1976.
Streptokinase.
Methods Enzymol.
45:244-257[Medline].
|
| 8.
|
Cederholm-Williams, S. A.,
F. Decock,
H. R. Linjen, and D. Collen.
1979.
Kinetics of the reactions between streptokinase, plasmin and alpha-2 antiplasmin.
Eur. J. Biochem.
100:125-132[Medline].
|
| 9.
|
Christner, R.,
Z. Li,
R. Raeder,
A. Podbielski, and M. D. P Boyle.
1997.
Identification of key gene products required for acquisition of plasmin-like enzymatic activity by group A streptococci.
J. Infect. Dis.
175:1115-1120[Medline].
|
| 10.
|
Collen, D.
1980.
On the regulation and control of fibrinolysis.
Thromb. Haemost.
43:77-89[Medline].
|
| 11.
|
Courtney, H. S.,
Y. Li,
J. B. Dale, and D. L. Hasty.
1994.
Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci.
Infect. Immun.
62:3937-3946[Abstract/Free Full Text].
|
| 12.
|
Facklam, R. R., and L. Rutledge.
1984.
Physiologic and in vitro virulence differences among four beta-hemolytic group C streptococcus species, p. 64-69.
In
Y. Kimura, S. Kotami, and Y. Shiokawa (ed.), Proceedings of the IXth International Symposium on Streptococci and Streptococcal Diseases. Reedbooks, Berkshire, United Kingdom.
|
| 13.
|
Huang, T. T.,
H. Malke, and J. J. Ferretti.
1989.
Heterogeneity of the streptokinase gene in group A streptococci.
Infect. Immun.
57:502-506[Abstract/Free Full Text].
|
| 14.
|
Kruithof, E. K.
1988.
Plasminogen activator inhibitors a review.
Enzyme
40:113-121[Medline].
|
| 15.
|
Kuusela, P.,
M. Ullberg,
O. Saksela, and G. Kronvall.
1992.
Tissue-type plasminogen activator-mediated activation of plasminogen on the surface of group A, C, and G streptococci.
Infect. Immun.
60:196-201[Abstract/Free Full Text].
|
| 16.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 17.
|
Lottenberg, R.,
C. C. Broder, and M. D. P. Boyle.
1987.
Identification of a specific receptor for plasmin on a group A streptococcus.
Infect. Immun.
55:1914-1928[Abstract/Free Full Text].
|
| 18.
|
Lottenberg, R.,
L. E. Desjardin,
H. Wang, and M. D. P. Boyle.
1992.
Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity.
J. Infect. Dis.
166:436-440[Medline].
|
| 19.
|
Lottenberg, R.,
F. R. Dolly, and C. S. Kitchens.
1985.
Recurrent thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
Am. J. Hematol.
19:181-193[Medline].
|
| 20.
|
Malke, H.,
U. Mechold,
K. Gase, and D. Gerlach.
1994.
Inactivation of the streptokinase gene prevents Streptococcus equisimilis H46A from acquiring cell-associated plasmin activity in the presence of plasminogen.
FEMS Microbiol. Lett.
116:107-112[Medline].
|
| 21.
|
Malke, H.,
B. Roe, and J. J. Ferretti.
1985.
Nucleotide sequence of the streptokinase gene from streptococcus equisimilis H46A.
Gene
34:357-362[Medline].
|
| 22.
|
Maniatis, T.,
E. F. Fritsch, and J. Sambrook.
1982.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 23.
|
Marcum, J. A., and D. L. Kline.
1983.
Species specificity of streptokinase.
Comp. Biochem. Physiol.
75:389-394.
|
| 24.
|
McCoy, H. E.,
C. C. Broder, and R. Lottenberg.
1991.
Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation.
J. Infect. Dis.
164:515-521[Medline].
|
| 25.
|
McNeill, H., and P. J. Jensen.
1990.
A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
Cell Regul.
1:843-852[Medline].
|
| 26.
|
Nowicki, S.,
D. Minning-Wenz,
K. H. Johnston, and R. Lottenberg.
1994.
Characterization of a novel streptokinase produced by Streptococcus equisimilis of non-human origin.
Thromb. Haemost.
72:595-603[Medline].
|
| 27.
|
Ossowski, L.
1992.
Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor and interstitial collagenase.
Cancer Res.
52:6754-6760[Abstract/Free Full Text].
|
| 28.
|
Plow, E. F.,
T. Herren,
A. Redlitz,
L. A. Miles, and J. L. Hoover-Plow.
1995.
The cell biology of the plasminogen system.
FASEB J.
9:939-945[Abstract].
|
| 29.
|
Pöllänen, J.,
R. W. Stephens, and A. Vaheri.
1991.
Directed plasminogen activation at the surface of normal and malignant cells.
Adv. Cancer Res.
57:273-328[Medline].
|
| 30.
|
Reich, R.,
E. W. Thompson,
Y. Iwamoto,
G. R. Martin,
J. R. Deason,
G. C. Fuller, and R. Miskin.
1988.
Effects of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells.
Cancer Res.
48:3307-3312[Abstract/Free Full Text].
|
| 31.
|
Strickland, S.,
E. Reich, and M. I. Sherman.
1976.
Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm.
Cell
9:231-240[Medline].
|
| 32.
|
Thorell, J. I., and B. G. Johnsson.
1971.
Enzymatic iodination of polypeptides with 125I to high specific activity.
Biochim. Biophys. Acta
251:363-368[Medline].
|
| 33.
|
Ullberg, M.,
G. Kronvall,
I. Karlsson, and B. Wiman.
1990.
Receptors for human plasminogen on gram-negative bacteria.
Infect. Immun.
58:21-25[Abstract/Free Full Text].
|
| 34.
|
van de Rijn, I., and R. E. Kessler.
1980.
Growth characteristics of group A streptococci in a new chemically defined medium.
Infect. Immun.
27:444-448[Abstract/Free Full Text].
|
| 35.
|
Vassalli, J. D.,
A. P. Sappino, and D. Belin.
1991.
The plasminogen activator/plasmin system.
J. Clin. Investig.
88:1067-1072.
|
| 36.
|
Verstraete, M.,
H. R. Lijnen, and D. Collen.
1995.
Thrombolytic agents in development.
Drugs
50:29-42[Medline].
|
| 37.
|
Wang, H.,
R. Lottenberg, and M. D. P. Boyle.
1994.
Analysis of plasmin(ogen) acquisition by clinical isolates of group A streptococci incubated in human plasma.
J. Infect. Dis.
169:143-149[Medline].
|
| 38.
|
Wang, H.,
R. Lottenberg, and M. D. P. Boyle.
1995.
A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci.
J. Infect. Dis.
171:85-92[Medline].
|
| 39.
|
Whitnack, E., and E. H. Beachey.
1982.
Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci.
J. Clin. Investig.
69:1042-1045.
|
| 40.
|
Whitnack, E., and E. H. Beachey.
1985.
Biochemical and biological properties of the binding of human fibrinogen to M protein in group A streptococci.
J. Bacteriol.
164:350-358[Abstract/Free Full Text].
|
| 41.
|
Wistedt, A. C.,
U. Ringdahl,
W. Muller-Esteri, and U. Sjöbring.
1995.
Identification of a plasminogen-binding motif in PAM, a bacterial surface protein.
Mol. Microbiol.
18:569-578[Medline].
|
| 42.
|
Wohl, R. C.,
L. Sinio,
L. Summaria, and K. C. Robbins.
1983.
Comparative activation kinetics of mammalian plasminogens.
Biochim. Biophys. Acta
745:20-31[Medline].
|
Infection and Immunity, December 1999, p. 6487-6495, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fu, Q., Figuera-Losada, M., Ploplis, V. A., Cnudde, S., Geiger, J. H., Prorok, M., Castellino, F. J.
(2008). The Lack of Binding of VEK-30, an Internal Peptide from the Group A Streptococcal M-like Protein, PAM, to Murine Plasminogen Is due to Two Amino Acid Replacements in the Plasminogen Kringle-2 Domain. J. Biol. Chem.
283: 1580-1587
[Abstract]
[Full Text]
-
Sun, H.
(2006). The interaction between pathogens and the host coagulation system.. Physiology
21: 281-288
[Abstract]
[Full Text]
-
Rezcallah, M. S., Boyle, M. D. P., Sledjeski, D. D.
(2004). Mouse skin passage of Streptococcus pyogenes results in increased streptokinase expression and activity. Microbiology
150: 365-371
[Abstract]
[Full Text]
-
Kalia, A., Bessen, D. E.
(2004). Natural Selection and Evolution of Streptococcal Virulence Genes Involved in Tissue-Specific Adaptations. J. Bacteriol.
186: 110-121
[Abstract]
[Full Text]
-
Gladysheva, I. P., Turner, R. B., Sazonova, I. Y., Liu, L., Reed, G. L.
(2003). Coevolutionary patterns in plasminogen activation. Proc. Natl. Acad. Sci. USA
100: 9168-9172
[Abstract]
[Full Text]